FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127872153> ?p ?o ?g. }

• W2127872153 endingPage "1152" @default.
• W2127872153 startingPage "1142" @default.
• W2127872153 abstract "Acquired resistance to proteasome inhibitors represents a considerable impediment to their effective clinical application. Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors. However, the mechanisms of acquired resistance to carfilzomib and oprozomib are incompletely understood, and effective strategies for overcoming this resistance are needed. Here, we developed models of acquired resistance to carfilzomib in two head and neck squamous cell carcinoma cell lines, UMSCC-1 and Cal33, through gradual exposure to increasing drug concentrations. The resistant lines R-UMSCC-1 and R-Cal33 demonstrated 205- and 64-fold resistance, respectively, relative to the parental lines. Similarly, a high level of cross-resistance to oprozomib, as well as paclitaxel, was observed, whereas only moderate resistance to bortezomib (8- to 29-fold), and low level resistance to cisplatin (1.5- to 5-fold) was seen. Synergistic induction of apoptosis signaling and cell death, and inhibition of colony formation followed co-treatment of acquired resistance models with carfilzomib and the histone deacetylase inhibitor (HDACi) vorinostat. Synergism was also seen with other combinations, including oprozomib plus vorinostat, or carfilzomib plus the HDACi entinostat. Synergism was accompanied by upregulation of proapoptotic Bik, and suppression of Bik attenuated the synergy. The acquired resistance models also exhibited elevated levels of MDR-1/P-gp. Inhibition of MDR-1/P-gp with reversin 121 partially overcame carfilzomib resistance in R-UMSCC-1 and R-Cal33 cells. Collectively, these studies indicate that combining carfilzomib or oprozomib with HDAC or MDR-1/P-gp inhibitors may be a useful strategy for overcoming acquired resistance to these proteasome inhibitors." @default.
• W2127872153 created "2016-06-24" @default.
• W2127872153 creator A5025740932 @default.
• W2127872153 creator A5055055532 @default.
• W2127872153 creator A5081411983 @default.
• W2127872153 date "2014-06-10" @default.
• W2127872153 modified "2023-10-11" @default.
• W2127872153 title "Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors" @default.
• W2127872153 cites W1851740405 @default.
• W2127872153 cites W1966094320 @default.
• W2127872153 cites W1966704794 @default.
• W2127872153 cites W1968881061 @default.
• W2127872153 cites W1970969296 @default.
• W2127872153 cites W1983318244 @default.
• W2127872153 cites W1984085407 @default.
• W2127872153 cites W1995895276 @default.
• W2127872153 cites W2007955491 @default.
• W2127872153 cites W2010163650 @default.
• W2127872153 cites W2010818204 @default.
• W2127872153 cites W2014404730 @default.
• W2127872153 cites W2016742872 @default.
• W2127872153 cites W2033944464 @default.
• W2127872153 cites W2039278049 @default.
• W2127872153 cites W2047542386 @default.
• W2127872153 cites W2068650355 @default.
• W2127872153 cites W2074669321 @default.
• W2127872153 cites W2077945404 @default.
• W2127872153 cites W2082863510 @default.
• W2127872153 cites W2089311432 @default.
• W2127872153 cites W2092502635 @default.
• W2127872153 cites W2097967561 @default.
• W2127872153 cites W2100510340 @default.
• W2127872153 cites W2100608938 @default.
• W2127872153 cites W2102088366 @default.
• W2127872153 cites W2104599023 @default.
• W2127872153 cites W2108235071 @default.
• W2127872153 cites W2110689098 @default.
• W2127872153 cites W2112497073 @default.
• W2127872153 cites W2115133998 @default.
• W2127872153 cites W2118820477 @default.
• W2127872153 cites W2124560610 @default.
• W2127872153 cites W2126267349 @default.
• W2127872153 cites W2126736616 @default.
• W2127872153 cites W2127760782 @default.
• W2127872153 cites W2129890171 @default.
• W2127872153 cites W2135481148 @default.
• W2127872153 cites W2147422161 @default.
• W2127872153 cites W2149340130 @default.
• W2127872153 cites W2152091753 @default.
• W2127872153 cites W2154343997 @default.
• W2127872153 cites W2156659570 @default.
• W2127872153 cites W2160015978 @default.
• W2127872153 cites W2163679078 @default.
• W2127872153 cites W2164706843 @default.
• W2127872153 cites W2165197609 @default.
• W2127872153 cites W2169155283 @default.
• W2127872153 doi "https://doi.org/10.4161/cbt.29452" @default.
• W2127872153 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4128857" @default.
• W2127872153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24915039" @default.
• W2127872153 hasPublicationYear "2014" @default.
• W2127872153 type Work @default.
• W2127872153 sameAs 2127872153 @default.
• W2127872153 citedByCount "20" @default.
• W2127872153 countsByYear W21278721532015 @default.
• W2127872153 countsByYear W21278721532016 @default.
• W2127872153 countsByYear W21278721532017 @default.
• W2127872153 countsByYear W21278721532018 @default.
• W2127872153 countsByYear W21278721532019 @default.
• W2127872153 countsByYear W21278721532020 @default.
• W2127872153 countsByYear W21278721532022 @default.
• W2127872153 crossrefType "journal-article" @default.
• W2127872153 hasAuthorship W2127872153A5025740932 @default.
• W2127872153 hasAuthorship W2127872153A5055055532 @default.
• W2127872153 hasAuthorship W2127872153A5081411983 @default.
• W2127872153 hasBestOaLocation W21278721531 @default.
• W2127872153 hasConcept C104317684 @default.
• W2127872153 hasConcept C121608353 @default.
• W2127872153 hasConcept C126322002 @default.
• W2127872153 hasConcept C203014093 @default.
• W2127872153 hasConcept C27740335 @default.
• W2127872153 hasConcept C2776262904 @default.
• W2127872153 hasConcept C2776364478 @default.
• W2127872153 hasConcept C2776530083 @default.
• W2127872153 hasConcept C2776833033 @default.
• W2127872153 hasConcept C2777478702 @default.
• W2127872153 hasConcept C2778305200 @default.
• W2127872153 hasConcept C2778367456 @default.
• W2127872153 hasConcept C2780108899 @default.
• W2127872153 hasConcept C502942594 @default.
• W2127872153 hasConcept C55493867 @default.
• W2127872153 hasConcept C64927066 @default.
• W2127872153 hasConcept C71924100 @default.
• W2127872153 hasConcept C86803240 @default.
• W2127872153 hasConcept C95444343 @default.
• W2127872153 hasConcept C98274493 @default.
• W2127872153 hasConceptScore W2127872153C104317684 @default.
• W2127872153 hasConceptScore W2127872153C121608353 @default.
• W2127872153 hasConceptScore W2127872153C126322002 @default.

• next